Reports Q3 consolidated adjusted EBITDA $986M. “The third quarter marks our tenth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health (BHC), excluding Bausch + Lomb, highlighting our team’s consistent execution and operational excellence. The completion of our acquisition of DURECT Corporation in the quarter further strengthens our growth platform in R&D, complementing our existing hepatology pipeline and broadening the reach of our diverse portfolio across therapeutic areas and geographies. As we approach the close of 2025, we remain focused on executing against our strategic priorities, driving strong year-end performance, and unlocking value for shareholders.” said Thomas Appio, CEO, Bausch Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health options imply 8.2% move in share price post-earnings
- Midday Fly By: Nvidia hits $5T market cap, Boeing takes big 777X charge
- Bausch Health leaves Medicaid, 340B program, STAT reports
- Bausch Health announces results of special meeting of shareholders
- Bausch Health’s Solta Medical featured on ‘The Balancing Act’